Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: David Jones who wrote (1617)	9/14/1998 11:38:00 PM
From: Marvin Frank	Read Replies (1) \| Respond to of 4140

Latest news from ophthalmic journal praises SNRS laser procedure very highly with excellent results and NO side effects. The procedure is in phase III trials with need for 400 patients. This should be easy to accomplish since FDA approved bilateral treatment. Two articles seen in Ophthalmology Times this week by excellent researchers. I predict that the company should do well with this laser which is far less costly than the VISX instrument.

To: David Jones who wrote (1617)	10/1/1998 8:44:00 PM
From: David Jones	Read Replies (2) \| Respond to of 4140

Well I'm to page 21 of form S2. For a second I though dilution then I seen it as just company financial blood and positioning for PMA. They have an show coming up here on the 3ed. I'm wondering what Omnicom has put together for marketing? I suppose if they can put together a reasonable presentation for the 3ed and SNRS can get PMA before the next show in Nov, that would be a 'Good Thing'. Could actually mean domestic sales; cool. Or am I too optimistic? Davej